Cargando…
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illn...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576805/ https://www.ncbi.nlm.nih.gov/pubmed/34446469 http://dx.doi.org/10.1183/13993003.01724-2021 |
_version_ | 1784595954062589952 |
---|---|
author | Devos, Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tomé Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler, Lucie Moonen, Martial Moutschen, Michel Van Regenmortel, Niels Ariën, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert |
author_facet | Devos, Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tomé Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler, Lucie Moonen, Martial Moutschen, Michel Van Regenmortel, Niels Ariën, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert |
author_sort | Devos, Timothy |
collection | PubMed |
description | BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT(50))) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806–906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT(50)) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59–1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality. |
format | Online Article Text |
id | pubmed-8576805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-85768052021-11-10 Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma Devos, Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tomé Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler, Lucie Moonen, Martial Moutschen, Michel Van Regenmortel, Niels Ariën, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert Eur Respir J Original Research Articles BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT(50))) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806–906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT(50)) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59–1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality. European Respiratory Society 2022-02-10 /pmc/articles/PMC8576805/ /pubmed/34446469 http://dx.doi.org/10.1183/13993003.01724-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Devos, Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tomé Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler, Lucie Moonen, Martial Moutschen, Michel Van Regenmortel, Niels Ariën, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title_full | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title_fullStr | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title_full_unstemmed | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title_short | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
title_sort | early high antibody titre convalescent plasma for hospitalised covid-19 patients: dawn-plasma |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576805/ https://www.ncbi.nlm.nih.gov/pubmed/34446469 http://dx.doi.org/10.1183/13993003.01724-2021 |
work_keys_str_mv | AT devostimothy earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT vanthilloquentin earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT compernolleveerle earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT najdovskitome earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT romanomarta earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT daubynicolas earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT jadotlaurent earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT leysmathias earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT maillartevelyne earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT loofsarah earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT seylerlucie earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT moonenmartial earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT moutschenmichel earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT vanregenmortelniels earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT arienkevink earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT barbezangecyril earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT betrainsalbrecht earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT gariglianymutien earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT engelenmatthiasm earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT gyselinckiwein earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT maespiet earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT schauwvlieghealexander earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT liesenborghslaurens earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT belmansann earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT verhammepeter earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma AT meyfroidtgeert earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma |